US Equities Analysis

BSX — Boston Scientific

BSX Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 71.85B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 0.56 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 20.6%
Profit Margins 17.29%
Return on Equity 14.66%
Return on Assets 6.07%
Free Float 1.48B
Short Int % Utilisation 3.87%

2.2 Growth

Metric Value
Revenue Growth 11.6%
Free Cash Flow 2.81B
EBITDA 14.85 (Ratio)
Enterprise Value 81.67B
EV/Revenue 3.96
EV/EBITDA 14.85

Revenue growth of 11.6% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 5.75%
Risk / Std Dev (Ann.) 25.68%
Sharpe Ratio (rf=4.5%) 0.05
Beta 0.56

2.5 Valuation

Metric Value
P/E (Forward) 12.97
Price/Book 2.62
EV/Revenue 3.96
EV/EBITDA 14.85
Enterprise Value / NOPAT 17.86
FCF Yield (%) 4.14%
Price / Earnings 19.08
Price / Book 2.62
Enterprise Value / EBITDA 14.11

Forward P/E of 13x is within a reasonable range for the company’s peer group.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of 5.8% with annualised volatility of 25.7%, yielding a Sharpe ratio of 0.05 (rf=4.5%). The risk-adjusted return is positive but modest on a historical basis. With a beta of 0.6, the stock is less volatile than the market, offering relative downside protection.


us-equitystockequitybsxhealth-carehealth-care-equipmentnasdaq